Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MATTEL INC /DE/MAT · Entity 1046 | Chief Financial Officer | August 01, 2017 | August 03, 2017 |
| Polaris Inc.PII · Entity 760 | Director | May 01, 2025 | May 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MATTEL INC /DE/
Report date August 01, 2017 · Filed August 03, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 268,448 |
Ending reported balance
After 2017-08-01 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2017-08-01 · Exercise / conversion · Acquired 9,929 · Balance 268,498 F1: As reported on a Form 4 dated July 31, 2014 and filed on August 4, 2014, the Reporting Person received a grant of 19,858 Restricted Stock Units ("RSUs" or "Units") on August 1, 2014. The RSUs vest as to 50% of the Units on the second anniversary of the date of grant and as to the remaining 50% of the Units on the third anniversary of the date of grant. On each vesting date, for each Unit vesting on such date, the Reporting Person will receive one share of Mattel, Inc. Common Stock (or, at the election of Mattel, Inc., a cash amount equal to the fair market value of one share of Common Stock on the date of vesting), subject to tax withholding. On August 1, 2017, the remaining 50% of these RSUs vested, resulting in the issuance of 9,929 shares of Mattel, Inc. Common Stock. Row 2 · 2017-08-01 · Tax withholding · Disposed 3,732 · Balance 264,766 F2: Pursuant to the terms of the August 1, 2014 RSU grant, 3,732 shares of Mattel, Inc. Common Stock were automatically withheld at vesting to cover required tax withholding. Row 3 · 2017-08-01 · Exercise / conversion · Acquired 5,900 · Balance 270,666 F3: As reported on a Form 4 dated August 1, 2016 and filed on August 3, 2016, the Reporting Person received a grant of 17,879 RSUs on August 1, 2016. The RSUs vest as to (a) 33% of the Units granted on the first anniversary of the date of grant, (b) an additional 33% of the Units granted on the second anniversary of the date of grant, and (c) the remaining 34% of the Units granted on the third anniversary of the date of grant. On each vesting date, for each Unit vesting on such date, the Reporting Person will receive one share of Mattel, Inc. Common Stock (or, at the election of Mattel, Inc., a cash amount equal to the fair market value of one share of Common Stock on the date of vesting), subject to tax withholding. On August 1, 2017, the first 33% of these RSUs vested, resulting in the issuance of 5,900 shares of Mattel, Inc. Common Stock. Row 4 · 2017-08-01 · Tax withholding · Disposed 2,218 · Balance 268,448 F4: Pursuant to the terms of the August 1, 2016 RSU grant, 2,218 shares of Mattel, Inc. Common Stock were automatically withheld at vesting to cover required tax withholding. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-08-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-08-01 · Exercise / conversion · Disposed 9,929 · Balance 0 F1: As reported on a Form 4 dated July 31, 2014 and filed on August 4, 2014, the Reporting Person received a grant of 19,858 Restricted Stock Units ("RSUs" or "Units") on August 1, 2014. The RSUs vest as to 50% of the Units on the second anniversary of the date of grant and as to the remaining 50% of the Units on the third anniversary of the date of grant. On each vesting date, for each Unit vesting on such date, the Reporting Person will receive one share of Mattel, Inc. Common Stock (or, at the election of Mattel, Inc., a cash amount equal to the fair market value of one share of Common Stock on the date of vesting), subject to tax withholding. On August 1, 2017, the remaining 50% of these RSUs vested, resulting in the issuance of 9,929 shares of Mattel, Inc. Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 11,979 |
Reported balance
After 2017-08-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-08-01 · Exercise / conversion · Disposed 5,900 · Balance 11,979 F3: As reported on a Form 4 dated August 1, 2016 and filed on August 3, 2016, the Reporting Person received a grant of 17,879 RSUs on August 1, 2016. The RSUs vest as to (a) 33% of the Units granted on the first anniversary of the date of grant, (b) an additional 33% of the Units granted on the second anniversary of the date of grant, and (c) the remaining 34% of the Units granted on the third anniversary of the date of grant. On each vesting date, for each Unit vesting on such date, the Reporting Person will receive one share of Mattel, Inc. Common Stock (or, at the election of Mattel, Inc., a cash amount equal to the fair market value of one share of Common Stock on the date of vesting), subject to tax withholding. On August 1, 2017, the first 33% of these RSUs vested, resulting in the issuance of 5,900 shares of Mattel, Inc. Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectIn 401(k) | 17,247 |
Reported balance
Holding disclosure · report date 2017-08-01 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 17,247 F5: As of August 1, 2017, the Reporting Person had a balance of $340,117.77 in the Mattel Stock Fund of Mattel, Inc.'s 401(k) plan, the Personal Investment Plan ("PIP"). The number of shares has been calculated by the plan administrator for the PIP. |
Filing footnotes · ownership attribution and instrument terms
F1: As reported on a Form 4 dated July 31, 2014 and filed on August 4, 2014, the Reporting Person received a grant of 19,858 Restricted Stock Units ("RSUs" or "Units") on August 1, 2014. The RSUs vest as to 50% of the Units on the second anniversary of the date of grant and as to the remaining 50% of the Units on the third anniversary of the date of grant. On each vesting date, for each Unit vesting on such date, the Reporting Person will receive one share of Mattel, Inc. Common Stock (or, at the election of Mattel, Inc., a cash amount equal to the fair market value of one share of Common Stock on the date of vesting), subject to tax withholding. On August 1, 2017, the remaining 50% of these RSUs vested, resulting in the issuance of 9,929 shares of Mattel, Inc. Common Stock.
F2: Pursuant to the terms of the August 1, 2014 RSU grant, 3,732 shares of Mattel, Inc. Common Stock were automatically withheld at vesting to cover required tax withholding.
F3: As reported on a Form 4 dated August 1, 2016 and filed on August 3, 2016, the Reporting Person received a grant of 17,879 RSUs on August 1, 2016. The RSUs vest as to (a) 33% of the Units granted on the first anniversary of the date of grant, (b) an additional 33% of the Units granted on the second anniversary of the date of grant, and (c) the remaining 34% of the Units granted on the third anniversary of the date of grant. On each vesting date, for each Unit vesting on such date, the Reporting Person will receive one share of Mattel, Inc. Common Stock (or, at the election of Mattel, Inc., a cash amount equal to the fair market value of one share of Common Stock on the date of vesting), subject to tax withholding. On August 1, 2017, the first 33% of these RSUs vested, resulting in the issuance of 5,900 shares of Mattel, Inc. Common Stock.
F4: Pursuant to the terms of the August 1, 2016 RSU grant, 2,218 shares of Mattel, Inc. Common Stock were automatically withheld at vesting to cover required tax withholding.
F5: As of August 1, 2017, the Reporting Person had a balance of $340,117.77 in the Mattel Stock Fund of Mattel, Inc.'s 401(k) plan, the Personal Investment Plan ("PIP"). The number of shares has been calculated by the plan administrator for the PIP.
Polaris Inc.
Report date May 01, 2025 · Filed May 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,075.65 |
Reported balance
After 2025-05-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-05-01 · Grant · Acquired 4,320 · Balance 22,075.65 F1: The reported transaction involved the crediting of 4,320 deferred stock units granted under the Polaris Inc. 2024 Omnibus Incentive Plan, each of which may be settled in one share of common stock pursuant to the Company's Deferred Compensation Plan for Directors. The total reported in column 5 includes the 4,320 newly acquired deferred stock units, and 731.60 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction involved the crediting of 4,320 deferred stock units granted under the Polaris Inc. 2024 Omnibus Incentive Plan, each of which may be settled in one share of common stock pursuant to the Company's Deferred Compensation Plan for Directors. The total reported in column 5 includes the 4,320 newly acquired deferred stock units, and 731.60 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Niagen Bioscience, Inc.
Report date August 12, 2022 · Filed August 12, 2022
Section 16 reporting ended · disclosed 2022-08-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 89,189 |
Reported balance
After 2022-08-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-08-12 · Grant · Acquired 89,189 · Balance 89,189 F1: On August 12, 2022, the Reporting Person was awarded Restricted Stock Units ("RSUs") in connection with the Reporting Person's transition services to the Issuer and the related consulting agreement with the Reporting Person (the "Consultant Agreement") effective August 13, 2022. The reporting person was terminated as the Chief Financial Officer of the Issuer effective August 12, 2022. F2: RSUs shall vest and be settled in shares of Common Stock upon the earlier of the expiration of the Consultant Agreement, which is expected to be on or around November 11, 2022, or the earlier termination of the Consultant Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 12, 2022, the Reporting Person was awarded Restricted Stock Units ("RSUs") in connection with the Reporting Person's transition services to the Issuer and the related consulting agreement with the Reporting Person (the "Consultant Agreement") effective August 13, 2022. The reporting person was terminated as the Chief Financial Officer of the Issuer effective August 12, 2022.
F2: RSUs shall vest and be settled in shares of Common Stock upon the earlier of the expiration of the Consultant Agreement, which is expected to be on or around November 11, 2022, or the earlier termination of the Consultant Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2025 Filed May 5, 2025 21:05 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 4,320 | $34.72 | $149,990.40 |
DisclosureSEC source: 0001628280-25-022254 · wk-form4_1746479115.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,075.65 F1 · balance_after: The reported transaction involved the crediting of 4,320 deferred stock units granted under the Polaris Inc. 2024 Omnibus Incentive Plan, each of which may be settled in one share of common stock pursuant to the Company's Deferred Compensation Plan for Directors. The total reported in column 5 includes the 4,320 newly acquired deferred stock units, and 731.60 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan. Read SEC document |
| April 25, 2024 Filed Apr 29, 2024 22:12 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 1,801 | $83.28 | $149,987.28 |
DisclosureSEC source: 0001628280-24-019136 · wk-form4_1714428733.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,024.05 F1 · balance_after: The reported transaction involved the crediting of 1,801 deferred stock units granted under the Polaris Inc. 2024 Omnibus Incentive Plan, each of which may be settled in one share of common stock pursuant to the Company's Deferred Compensation Plan for Directors. The total reported in column 5 includes the 1,801 newly acquired deferred stock units, and 214.76 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 21:34 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 359.27 | $102.64 | $36,875.47 |
DisclosureSEC source: 0001628280-23-033849 · wk-form4_1696455251.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,008.29 F1 · balance_after: The reported transaction involved the crediting of 359.27 Common Stock Equivalents (CSEs), each of which may be settled in one share of common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors (DC Plan) in connection with the reporting person's election to defer receipt of the reporting person's quarterly cash retainer payment. The total reported in column 5 includes the 359.27 newly acquired CSEs, and 88.58 deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan. The total in box 5 of Table I also reflects a reduction of 84.34 CSEs and deferred stock units that were initially reported on the Form 4 filed on July 5, 2023 and inadvertently reported in duplicate on the Form 4 filed on July 31, 2023. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 21:03 UTC | Polaris Inc. PII · Entity 760 | SaleCommon Stock | 3,225 | $133.28 | $429,828.00 |
DisclosureSEC source: 0001628280-23-027827 · wk-form4_1691442226.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,644.78 Read SEC document |
| July 27, 2023 Filed Aug 1, 2023 01:33 UTC | Polaris Inc. PII · Entity 760 | SaleCommon Stock | 1,615 | $134.33 | $216,942.95 |
DisclosureSEC source: 0001628280-23-026317 · wk-form4_1690853616.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,869.78 F1 · balance_after: The reported transaction involves the deemed sale of 1,615 Common Stock Equivalents ("CSEs") granted since 2022, each of which may be settled in one share of Polaris common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors ("DC Plan") in connection with the reporting person's election to diversify such CSEs into alternative investment options available under the DC Plan. The reported transaction also includes 84.34 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 21:16 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 301.69 | $122.23 | $36,875.57 |
DisclosureSEC source: 0001628280-23-024305 · wk-form4_1688591800.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,400.44 F1 · balance_after: The reported transaction involved the crediting of 301.69 Common Stock Equivalents (CSEs), each of which may be settled in one share of common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors (DC Plan) in connection with the reporting person's election to defer receipt of the reporting person's quarterly cash retainer payment. The total reported in column 5 includes the 301.69 newly acquired CSEs, and 84.34 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan. Read SEC document |
| April 27, 2023 Filed May 1, 2023 21:13 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 1,380 | $108.71 | $150,019.80 |
DisclosureSEC source: 0001628280-23-014648 · wf-form4_168297561339280.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,014.41 F1 · balance_after: The reported transaction involved the crediting of 1,380 deferred stock units granted under the Polaris Industries Inc. 2007 Omnibus Incentive Plan, each of which may be settled in one share of common stock pursuant to the Company's Deferred Compensation Plan for Directors. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 21:12 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 309.13 | $111.20 | $34,375.26 |
DisclosureSEC source: 0001628280-23-010883 · wf-form4_168072914868111.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,634.41 F1 · balance_after: The reported transaction involved the crediting of 309.13 Common Stock Equivalents (CSEs), each of which may be settled in one share of common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors (DC Plan) in connection with the reporting person's election to defer receipt of the reporting person's quarterly cash retainer payment. The total reported in column 5 includes the 309.13 newly acquired CSEs, and 84.81 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:02 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 342.04 | $100.50 | $34,375.02 |
DisclosureSEC source: 0001628280-23-000493 · wf-form4_167295615542496.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,240.47 F1 · balance_after: The reported transaction involved the crediting of 342.04 Common Stock Equivalents (CSEs), each of which may be settled in one share of common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors (DC Plan) in connection with the reporting person's election to defer receipt of the reporting person's quarterly cash retainer payment. The total reported in column 5 includes the 342.04 newly acquired CSEs, and 139.13 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:06 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 175.39 | $98.00 | $17,188.22 |
DisclosureSEC source: 0001628280-22-026052 · wf-form4_166500399432086.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,759.3 F1 · balance_after: The reported transaction involved the crediting of 175.39 Common Stock Equivalents (CSEs), each of which may be settled in one share of common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors (DC Plan) in connection with the reporting person's election to defer receipt of the reporting person's quarterly cash retainer payment. The total reported in column 5 includes the 175.39 newly acquired CSEs, and 77.14 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan. Read SEC document |
| August 12, 2022 Filed Aug 12, 2022 21:09 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantRestricted Stock Unit · Derivative | 89,189 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-022757 · wf-form4_166035294656633.xml · derivative · entry 1 FARR KEVIN M · CIK 0001194262 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,189 Underlying: Common Stock · 89,189 shares Expires not disclosed F1 · derivative.exercise_price: On August 12, 2022, the Reporting Person was awarded Restricted Stock Units ("RSUs") in connection with the Reporting Person's transition services to the Issuer and the related consulting agreement with the Reporting Person (the "Consultant Agreement") effective August 13, 2022. The reporting person was terminated as the Chief Financial Officer of the Issuer effective August 12, 2022. F2 · derivative.exercise_date: RSUs shall vest and be settled in shares of Common Stock upon the earlier of the expiration of the Consultant Agreement, which is expected to be on or around November 11, 2022, or the earlier termination of the Consultant Agreement. F2 · derivative.expiration_date: RSUs shall vest and be settled in shares of Common Stock upon the earlier of the expiration of the Consultant Agreement, which is expected to be on or around November 11, 2022, or the earlier termination of the Consultant Agreement. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 21:26 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 170.13 | $101.03 | $17,188.23 |
DisclosureSEC source: 0001628280-22-018510 · wf-form4_165705635033784.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,506.77 F1 · balance_after: The reported transaction involved the crediting of 170.13 Common Stock Equivalents (CSEs), each of which may be settled in one share of common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors (DC Plan) in connection with the reporting person's election to defer receipt of the reporting person's quarterly cash retainer payment. The total reported in column 5 includes the 170.13 newly acquired CSEs, and 82.61 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan. Read SEC document |
| April 28, 2022 Filed May 2, 2022 21:31 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 1,486 | $97.63 | $145,078.18 |
DisclosureSEC source: 0001628280-22-011791 · wf-form4_165152705236216.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,254.03 F1 · balance_after: The reported transaction involved the crediting of 1,486 deferred stock units granted under the Polaris Industries Inc. 2007 Omnibus Incentive Plan, each of which may be settled in one share of common stock pursuant to the Company's Deferred Compensation Plan for Directors. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:08 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 149.73 | $106.44 | $15,937.26 |
DisclosureSEC source: 0001628280-22-008418 · wf-form4_164919288567384.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,768.03 F1 · balance_after: The reported transaction involved the crediting of 149.73 Common Stock Equivalents (CSEs), each of which may be settled in one share of common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors (DC Plan) in connection with the reporting person's election to defer receipt of the reporting person's quarterly cash retainer payment. The total reported in column 5 includes the 149.73 newly acquired CSEs, and 68.62 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 17:29 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 122,374 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001628280-22-003372 · wf-form4_164556897219267.xml · derivative · entry 1 FARR KEVIN M · CIK 0001194262 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,374 Underlying: Common Stock · 122,374 shares Expires 2032-02-16 F1 · shares: One-third of the shares subject to the option shall vest on February 17, 2023 and the remaining shares subject to the option shall vest in a series of 24 equal monthly installments thereafter. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:46 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 144.45 | $110.33 | $15,937.17 |
DisclosureSEC source: 0001628280-22-000366 · wf-form4_164142276047897.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,549.68 F1 · balance_after: The reported transaction involved the crediting of 144.45 Common Stock Equivalents (CSEs), each of which may be settled in one share of common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors (DC Plan) in connection with the reporting person's election to defer receipt of the reporting person's quarterly cash retainer payment. The total reported in column 5 includes the 144.45 newly acquired CSEs, and 64.27 deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan. Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 21:19 UTC | Polaris Inc. PII · Entity 760 | SaleCommon Stock | 10,168.96 | $115.27 | $1,172,176.02 |
DisclosureSEC source: 0001628280-21-021023 · wf-form4_163580154402437.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,340.96 F1 · balance_after: The reported transaction involves the deemed sale of 10,168.96 Common Stock Equivalents (CSEs) granted since 2013, each of which may be settled in one share of Polaris common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors ("DC Plan") in connection with the reporting person's election to diversify such CSEs into alternative investment options available under the DC Plan. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:15 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 273.64 | $121.25 | $33,178.85 |
DisclosureSEC source: 0001628280-21-019694 · wf-form4_163346849929716.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,509.9152 F1 · balance_after: The reported transaction involved the crediting of 273.64 Common Stock Equivalents (CSEs), each of which may be settled in one share of common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors (DC Plan) in connection with the reporting person's election to defer receipt of the reporting person's quarterly cash retainer payment. The total reported in column 5 includes the 273.64 newly acquired CSEs, and 50.7452 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:33 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 227.98 | $134.33 | $30,624.55 |
DisclosureSEC source: 0001628280-21-013541 · wf-form4_162560359901793.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,185.53 F1 · balance_after: The reported transaction involved the crediting of 227.98 Common Stock Equivalents (CSEs), each of which may be settled in one share of common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors (DC Plan) in connection with the reporting person's election to defer receipt of the reporting person's quarterly cash retainer payment. The total reported in column 5 includes the 227.98 newly acquired CSEs, and 99.46 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan. Read SEC document |
| April 29, 2021 Filed May 3, 2021 21:40 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 1,018 | $137.52 | $139,995.36 |
DisclosureSEC source: 0001209191-21-029569 · doc4.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,858.09 F1 · balance_after: The reported transaction involved the crediting of 1,018 deferred stock units granted under the Polaris Inc. 2007 Omnibus Incentive Plan, each of which may be settled in one share of common stock pursuant to the Company's Deferred Compensation Plan for Directors. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 22:05 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 217.71 | $134.93 | $29,375.61 |
DisclosureSEC source: 0001209191-21-025351 · doc4.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,840.09 F1 · balance_after: The reported transaction involved the crediting of 217.71 Common Stock Equivalents (CSEs), each of which may be settled in one share of common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors (DC Plan) in connection with the reporting person's election to defer receipt of the reporting person's quarterly cash retainer payment. The total reported in column 5 includes the 217.71 newly acquired CSEs, and 86.58 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 18:47 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 28,461 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001415889-21-001552 · form4-03172021_030343.xml · derivative · entry 1 FARR KEVIN M · CIK 0001194262 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,461 Underlying: Common Stock · 28,461 shares Expires 2031-03-14 F1 · derivative.exercise_date: Options vest 33% on March 15, 2022 and thereafter 1/36th vest each month. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 19:42 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 306.92 | $95.71 | $29,375.31 |
DisclosureSEC source: 0001209191-21-001899 · doc4.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,535.8 F1 · balance_after: The reported transaction involved the crediting of 306.92 Common Stock Equivalents (CSEs), each of which may be settled in one share of common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors (DC Plan) in connection with the reporting person's election to defer receipt of the reporting person's quarterly cash retainer payment. The total reported in column 5 includes the 306.92 newly acquired CSEs, and 121.86 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan. Read SEC document |
| November 06, 2020 Filed Nov 6, 2020 16:20 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 5,000 | $4.43 | $22,150.00 |
DisclosureSEC source: 0001415889-20-002560 · form4-11062020_011109.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,625 Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 21:35 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 310.72 | $94.54 | $29,375.47 |
DisclosureSEC source: 0001209191-20-053804 · doc4.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,107.03 F1 · balance_after: The reported transaction involved the crediting of 310.72 Common Stock Equivalents (CSEs), each of which may be settled in one share of common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors (DC Plan) in connection with the reporting person's election to defer receipt of the reporting person's quarterly cash retainer payment. The total reported in column 5 includes the 310.72 newly acquired CSEs, and 123.28 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 18:38 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 276.37 | $90.91 | $25,124.80 |
DisclosureSEC source: 0001209191-20-040109 · doc4.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,673.04 F1 · balance_after: The reported transaction involved the crediting of 276.37 Common Stock Equivalents (CSEs), each of which may be settled in one share of common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors (DC Plan) in connection with the reporting person's election to defer receipt of the reporting person's quarterly cash retainer payment. The total reported in column 5 includes the 276.37 newly acquired CSEs, and 116.77 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan. Read SEC document |
| April 30, 2020 Filed May 4, 2020 20:35 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 1,833 | $70.93 | $130,014.69 |
DisclosureSEC source: 0001209191-20-026795 · doc4.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,279.89 F1 · balance_after: The reported transaction involved the crediting of 1,833 deferred stock units granted under the Polaris Inc. 2007 Omnibus Incentive Plan, each of which may be settled in one share of common stock pursuant to the Company's Deferred Compensation Plan for Directors. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 19:16 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 636.93 | $46.12 | $29,375.21 |
DisclosureSEC source: 0001209191-20-023051 · doc4.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,446.89 F1 · balance_after: The reported transaction involved the crediting of 636.93 Common Stock Equivalents (CSEs), each of which may be settled in one share of common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors (DC Plan) in connection with the reporting person's election to defer receipt of the reporting person's quarterly cash retainer payment. The total reported in column 5 includes the 636.93 newly acquired CSEs, and 173.32 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 20:32 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 109,054 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001415889-20-000550 · form4-02272020_050256.xml · derivative · entry 1 FARR KEVIN M · CIK 0001194262 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,054 Underlying: Common Stock · 109,054 shares Expires 2030-02-25 F1 · derivative.exercise_date: Options vest 33% on February 25, 2021 and thereafter 1/36th vest each month. Read SEC document |
| February 25, 2020 Filed Nov 6, 2020 16:17 UTC Amendment | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 109,054 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001415889-20-002558 · form4a-11062020_011146.xml · derivative · entry 1 FARR KEVIN M · CIK 0001194262 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,054 Underlying: Common Stock · 109,054 shares Expires 2030-02-25 F1 · date: This Form 4 Amendment is being filed solely to add the Power of Attorney. F2 · derivative.exercise_date: Options vest 33% on February 25, 2021 and thereafter 1/36th vest each month. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 23:25 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 285.11 | $103.03 | $29,374.88 |
DisclosureSEC source: 0001209191-20-002102 · doc4.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,636.64 F1 · balance_after: The reported transaction involved the crediting of 285.11 Common Stock Equivalents (CSEs), each of which may be settled in one share of common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors (DC Plan) in connection with the reporting person's election to defer receipt of the reporting person's quarterly cash retainer payment. The total reported in column 5 includes the 285.11 newly acquired CSEs, and 91.83 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 22:01 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 335.79 | $87.48 | $29,374.91 |
DisclosureSEC source: 0001209191-19-052389 · doc4.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,259.7 F1 · balance_after: The reported transaction involved the crediting of 335.79 Common Stock Equivalents (CSEs), each of which may be settled in one share of common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors (DC Plan) in connection with the reporting person's election to defer receipt of the reporting person's quarterly cash retainer payment. The total reported in column 5 includes the 335.79 newly acquired CSEs, and 97.95 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 17:20 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 325.74 | $90.18 | $29,375.23 |
DisclosureSEC source: 0001209191-19-040766 · doc4.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,825.96 F1 · balance_after: The reported transaction involved the crediting of 325.74 Common Stock Equivalents (CSEs), each of which may be settled in one share of common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors (DC Plan) in connection with the reporting person's election to defer receipt of the reporting person's quarterly cash retainer payment. The total reported in column 5 includes the 325.74 newly acquired CSEs, and 96.19 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan. Read SEC document |
| April 25, 2019 Filed Apr 29, 2019 22:02 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 1,372 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-026453 · doc4.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,404.03 F1 · balance_after: The reported transaction involved the crediting of 1,372 deferred stock units granted under the Polaris Industries Inc. 2007 Omnibus Incentive Plan, each of which may be settled in one share of common stock pursuant to the Company's Deferred Compensation Plan for Directors. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:19 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 340.58 | $86.25 | $29,375.03 |
DisclosureSEC source: 0001209191-19-023441 · doc4.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,032.03 F1 · balance_after: The reported transaction involved the crediting of 340.58 Common Stock Equivalents (CSEs), each of which may be settled in one share of common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors (DC Plan) in connection with the reporting person's election to defer receipt of the reporting person's quarterly cash retainer payment. The total reported in column 5 includes the 340.58 newly acquired CSEs, and 87.28 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan. Read SEC document |
| March 15, 2019 Filed Mar 15, 2019 20:16 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 6,900 | $3.85 | $26,565.00 |
DisclosureSEC source: 0001415889-19-000340 · form4-03152019_050347.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,625 Read SEC document |
| March 14, 2019 Filed Mar 14, 2019 17:28 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 6,725 | $3.99 | $26,832.75 |
DisclosureSEC source: 0001415889-19-000324 · form4-03142019_020327.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,725 Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 21:05 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 7,300 | $3.62 | $26,426.00 |
DisclosureSEC source: 0001415889-19-000317 · form4-03132019_060329.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Read SEC document |
| March 11, 2019 Filed Mar 12, 2019 20:53 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 5,700 | $3.49 | $19,893.00 |
DisclosureSEC source: 0001415889-19-000310 · form4-03122019_050324.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,700 Read SEC document |
| February 26, 2019 Filed Mar 1, 2019 00:05 UTC | Polaris Inc. PII · Entity 760 | PurchaseCommon Stock | 1,125 | $88.59 | $99,660.38 |
DisclosureSEC source: 0001209191-19-014776 · doc4.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,604.18 Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 19:41 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 89,254 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001415889-19-000225 · form4-02222019_040226.xml · derivative · entry 1 FARR KEVIN M · CIK 0001194262 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,254 Underlying: Common Stock · 89,254 shares Expires 2029-02-21 F1 · derivative.exercise_date: Options vest 33% on February 21, 2020 and thereafter 1/36th vest each month. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 22:36 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 376.26 | $78.07 | $29,374.62 |
DisclosureSEC source: 0001209191-19-002153 · doc4.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,479.18 F1 · balance_after: The reported transaction involved the crediting of 376.26 Common Stock Equivalents (CSEs), each of which may be settled in one share of common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors (DC Plan) in connection with the reporting person's election to defer receipt of the reporting person's quarterly cash retainer payment. The total reported in column 5 includes the 376.26 newly acquired CSEs, and 91.38 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 21:59 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 292.29 | $100.50 | $29,375.15 |
DisclosureSEC source: 0001209191-18-054046 · doc4.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,011.53 F1 · balance_after: The reported transaction involved the crediting of 292.29 Common Stock Equivalents (CSEs), each of which may be settled in one share of common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors (DC Plan) in connection with the reporting person's election to defer receipt of the reporting person's quarterly cash retainer payment. The total reported in column 5 includes the 292.29 newly acquired CSEs, and 63.66 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan. Read SEC document |
| September 11, 2018 Filed Sep 11, 2018 16:48 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 5,000 | $3.50 | $17,500.00 |
DisclosureSEC source: 0001415889-18-001357 · form4-09112018_010923.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 20:05 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 237.84 | $123.51 | $29,375.62 |
DisclosureSEC source: 0001209191-18-040931 · doc4.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,655.59 F1 · balance_after: The reported transaction involved the crediting of 237.84 Common Stock Equivalents (CSEs), each of which may be settled in one share of common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors (DC Plan) in connection with the reporting person's election to defer receipt of the reporting person's quarterly cash retainer payment. The total reported in column 5 includes the 237.84 newly acquired CSEs, and 51.75 CSEs and deferred stock units acquired pursuant to the dividend reinvestment feature of the DC Plan. Read SEC document |
| May 18, 2018 Filed May 22, 2018 18:46 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 5,000 | $3.83 | $19,150.00 |
DisclosureSEC source: 0001415889-18-000796 · form4-05222018_030523.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| April 25, 2018 Filed Apr 27, 2018 19:54 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 1,237 | $105.14 | $130,058.18 |
DisclosureSEC source: 0001209191-18-026521 · doc4.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,366 F1 · balance_after: The reported transaction involved the crediting of 1,237 deferred stock units granted under the Polaris Industries Inc. 2017 Omnibus Incentive Plan, each of which may be settled in one share of common stock pursuant to the Company's Deferred Compensation Plan for Directors. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 22:04 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 260.39 | $112.81 | $29,374.60 |
DisclosureSEC source: 0001209191-18-023871 · doc4.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,129 F1 · balance_after: The reported transaction involved the crediting of 260.39 Common Stock Equivalents (CSEs), each of which may be settled in one share of common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors (DC Plan) in connection with the reporting person's election to defer receipt of the reporting person's quarterly cash retainer payment. The total reported in column 5 includes the 260.39 newly acquired CSEs, and 49.51 CSEs and DSUs acquired pursuant to the dividend reinvestment feature of the DC Plan. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 20:52 UTC | Polaris Inc. PII · Entity 760 | GrantCommon Stock | 232.69 | $126.24 | $29,374.79 |
DisclosureSEC source: 0001209191-18-001844 · doc4.xml · nonDerivative · entry 1 FARR KEVIN M · CIK 0001194262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,819.1 F1 · balance_after: The reported transaction involved the crediting of 232.69 Common Stock Equivalents (CSEs), each of which may be settled in one share of common stock, to the reporting person's account under the Company's Deferred Compensation Plan for Directors (DC Plan) in connection with the reporting person's election to defer receipt of the reporting person's quarterly cash retainer payment. The total reported in column 5 includes the 232.69 newly acquired CSEs, and 43.77 CSEs and DSUs acquired pursuant to the dividend reinvestment feature of the DC Plan. Read SEC document |
| October 05, 2017 Filed Oct 10, 2017 16:25 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantStock Option (right to buy) · Derivative | 1,000,000 | $0.00 Strike: $4.24 | $0.00 |
DisclosureSEC source: 0001209191-17-056437 · doc4.xml · derivative · entry 1 FARR KEVIN M · CIK 0001194262 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2027-10-04 F1 · derivative.exercise_date: The number of shares subject to the option shall vest in equal monthly installments over three years such that all the shares subject to the option shall have vested on the third anniversary of October 5, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.